Biocon Biologics secures market entry for Yesafili in US

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon Biologics to launch Yesafili in the US by the second half of 2026, or earlier under certain conditions. Yesafili, already approved by the USFDA, is intended for treating various ophthalmology conditions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V0YZ6CP
via IFTTT